Search NLS News

Spago Nanomedical has completed the studies in the regulatory preclinical program with its leading candidate drug Tumorad (SN201). It displays a good safety margin to clinically relevant doses, states the company. “The completion of the regulatory preclinical studies is an important step towards the clinical development phase. The preparations for the first study with SN201 […]

Mercodia has announced the appointment of Jörgen Dahlström as new Chief Executive Officer. Dahlström holds a PhD in immunology and has held several different management positions at a number of international life science companies over the last 20 years. He will become the 3rd CEO in the company’s 30-year history. “Mercodia is a very exciting […]

BICO has been awarded this year’s SwedenBIO Award for showcasing the power of the Swedish life-science industry on the global arena and its visionary business model and remarkable growth. The bio convergence company, BICO, has received SwedenBIO’s Award which was announced in connection with SwedenBIO’s Annual Summit in Stockholm. Presented for the last fifteen years, […]

Alvotech and Oaktree Acquisition Corp II, a special purpose acquisition company sponsored by an affiliate of Oaktree Capital Management, have entered into a definitive merger agreement. Upon completion of the transaction, the combined company’s securities are expected to be traded on NASDAQ under the symbol “ALVO.” “Alvotech is in a unique position to impact the […]

AstraZeneca has entered into a new global development and commercialization agreement with Ionis Pharmaceuticals for eplontersen, formerly known as IONIS-TTR-LRX. Eplontersen is a ligand-conjugated antisense investigational medicine currently in Phase III clinical trials for amyloid transthyretin cardiomyopathy (ATTR-CM) and amyloid transthyretin polyneuropathy (ATTR-PN). It is designed to reduce the production of transthyretin (TTR protein) to […]

Enrollment of patients in the first clinical trial at the Saint Louis hospital in Paris, France, was initiated December 7th. The targeted treatment, SXR1096, has the potential of becoming the first available treatment of Netherton syndrome and meet a great patient need, the company states. Sixera has diligently been developing a new series of specific […]

Industrifonden has announced that Peter Wolpert has been appointed its new CEO. Wolpert has extensive experience developing and taking life science and tech companies to market, states Industrifonden. He will take up the helm at Industrifonden in March 2022 and he succeeds David Sonnek, who joins Navigare Ventures. “We are very pleased to have recruited […]

Immedica Pharma has announced the successful outcome from the Pegzilarginase Phase 3 Study, presented by its partner Aeglea BioTherapeutics. “I am pleased to see that these study results give hope for improved treatment options for patients with the severe and debilitating disease arginase-1 deficiency. Immedica plans to submit an EMA-application in 2022 which, if approved, […]

XNK Therapeutics will perform a proof of concept study in acute myeloid leukemia (AML) using patient samples from The University of Texas MD Anderson Cancer Center. The proof of concept study is to determine feasibility to expand and activate NK cells from patients with AML using XNK’s platform. The goal is to establish patient selection […]

Lundbeck has announced that Anders Götzsche, Chief Financial Officer (CFO), will depart Lundbeck to become CFO of another company in Denmark. He will leave Lundbeck no later than May 2022. “Anders has been CFO of Lundbeck for over 14 years, including a short stint as interim Chief Executive Officer in 2017-2018. He has been instrumental […]